SEC Form S-3 filed by Aerovate Therapeutics Inc.
SECURITIES AND EXCHANGE COMMISSION
THE SECURITIES ACT OF 1933
|
Delaware
|
| |
83-1377888
|
|
|
(State or other jurisdiction of
incorporation or organization) |
| |
(I.R.S. Employer
Identification No.) |
|
Waltham, MA 02451
(617) 443-2400
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)
Chief Executive Officer
Aerovate Therapeutics, Inc.
930 Winter Street, Suite M-500
Waltham, MA 02451
(617) 443-2400
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Alicia M. Tschirhart, Esq.
Goodwin Procter LLP
620 Eighth Avenue
New York, NY 10018
(212) 813-8800
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☒
|
|
| | | |
Emerging growth company
☒
|
|
| | |
Page
|
| |||
| | | | 1 | | | |
| | | | 3 | | | |
| | | | 4 | | | |
| | | | 6 | | | |
| | | | 7 | | | |
| | | | 8 | | | |
| | | | 13 | | | |
| | | | 20 | | | |
| | | | 21 | | | |
| | | | 24 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 27 | | | |
| | | | 28 | | |
Item
|
| |
Amount to
be paid |
| |||
SEC registration fee
|
| | | $ | 51,660 | | |
FINRA filing fee
|
| | | | 53,000 | | |
Printing and engraving expenses
|
| | | | * | | |
Legal fees and expenses
|
| | | | * | | |
Accounting fees and expenses
|
| | | | * | | |
Transfer agent fees and expenses
|
| | | | * | | |
Miscellaneous expenses
|
| | | | * | | |
Total
|
| | | $ | * | | |
|
Exhibit
Number |
| |
Exhibit
|
|
| 23.1 | | | | |
| 23.2 | | | | |
| 24.1 | | | | |
| 25.1** | | | Form T-1 Statement of Eligibility of Trustee for Senior Indenture under the Trust Indenture Act of 1939 | |
| 25.2** | | | Form T-1 Statement of Eligibility of Trustee for Subordinated Indenture under the Trust Indenture Act of 1939 | |
| 107 | | | |
Chief Executive Officer
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Timothy P. Noyes
Timothy P. Noyes
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
| |
June 10, 2024
|
|
|
/s/ George A. Eldridge
George A. Eldridge
|
| |
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer) |
| |
June 10, 2024
|
|
|
/s/ Habib Dable
Habib Dable
|
| |
Director
|
| |
June 10, 2024
|
|
|
/s/ Allison Dorval
Allison Dorval
|
| |
Director
|
| |
June 10, 2024
|
|
|
/s/ David Grayzel, M.D.
David Grayzel, M.D.
|
| |
Director
|
| |
June 10, 2024
|
|
|
/s/ Mark Iwicki
Mark Iwicki
|
| |
Director
|
| |
June 10, 2024
|
|
|
/s/ Maha Katabi, Ph.D.
Maha Katabi, Ph.D.
|
| |
Director
|
| |
June 10, 2024
|
|
|
/s/ Joshua Resnick, M.D.
Joshua Resnick, M.D.
|
| |
Director
|
| |
June 10, 2024
|
|
|
/s/ Donald J. Santel
Donald J. Santel
|
| |
Director
|
| |
June 10, 2024
|
|